Provided are anti-BMP4 antibodies binding to a conformational epitope located within the BMPRla binding site of BMP4 and pharmaceutical uses thereof.
Figure 5 Kinetic analysis for BMP binding.
Binding of VHHs to the different BMPs was tested in a direct SPR assay. The graphs show two replicate ligand injections at just one concentration of ligand.
Calpe, S., Wagner, K., El Khattabi, M., Rutten, L., Zimberlin, C., Dolk, E., ... & Krishnadath, K. K. (2015). Effective inhibition of bone morphogenetic protein function by highly specific llama-derived antibodies. Molecular cancer therapeutics, 14(11), 2527-2540.
Figure 6 Kinetic analysis for BMP binding.
Epitope binning of VHH-coated chip plates. BMP4 (1.0 mg/mL) was injected on the chip followed by the injection of a second VHH (2.0 mg/mL) or the corresponding controls.
Calpe, S., Wagner, K., El Khattabi, M., Rutten, L., Zimberlin, C., Dolk, E., ... & Krishnadath, K. K. (2015). Effective inhibition of bone morphogenetic protein function by highly specific llama-derived antibodies. Molecular cancer therapeutics, 14(11), 2527-2540.
Figure 7 VHH biheads inhibit endogenous BMP function.
BMP activity of conditioned media of organoids cultured at the indicated conditions for 3 days.
Calpe, S., Wagner, K., El Khattabi, M., Rutten, L., Zimberlin, C., Dolk, E., ... & Krishnadath, K. K. (2015). Effective inhibition of bone morphogenetic protein function by highly specific llama-derived antibodies. Molecular cancer therapeutics, 14(11), 2527-2540.
Figure 8 VHH biheads inhibit endogenous BMP function.
Number of organoids formed in cultures of mouse intestinal organoids grown for 5 days at the indicated conditions.
Calpe, S., Wagner, K., El Khattabi, M., Rutten, L., Zimberlin, C., Dolk, E., ... & Krishnadath, K. K. (2015). Effective inhibition of bone morphogenetic protein function by highly specific llama-derived antibodies. Molecular cancer therapeutics, 14(11), 2527-2540.
Figure 9 Anti-BMP4 VHHs inhibit cancer-derived BMP signals.
C2C12 cells were incubated with conditioned media of the indicated cancer cell lines. C4C4, C8C8, or human Fc-Noggin were added at the same time at a concentration of 500 ng/mL for 16 hours.
Calpe, S., Wagner, K., El Khattabi, M., Rutten, L., Zimberlin, C., Dolk, E., ... & Krishnadath, K. K. (2015). Effective inhibition of bone morphogenetic protein function by highly specific llama-derived antibodies. Molecular cancer therapeutics, 14(11), 2527-2540.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-2244z | Mouse Anti-BMP4 Recombinant Antibody (clone 18H6) | WB, ELISA, FC, ICC, IHC | Mouse IgG1 |
MOB-1495MZ | Mouse Anti-BMP4 Recombinant Antibody (clone 20G5C5) | ELISA, ICC, WB | Mouse IgG1 |
ZG-0339F | Mouse Anti-BMP4 Recombinant Antibody (ZG-0339F) | WB, ELISA | Mouse IgG |
VS3-FY162 | Recombinant Rabbit Anti-BMP4 Antibody (clone R01-2G4) | WB, ICC, IF, IP | Rabbit IgG |
VS4-WK50 | Rabbit Anti-BMP4 Recombinant Antibody (clone 19B7) | ELISA, WB, IF | Rabbit IgG |
There are currently no Customer reviews or questions for HPAB-0357-YC-VHH. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.